Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Bank of America Corp DE

Bank of America Corp DE lessened its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 29.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,187 shares of the company's stock after selling 14,504 shares during the quarter. Bank of America Corp DE owned approximately 0.07% of Enliven Therapeutics worth $769,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ELVN. Tower Research Capital LLC TRC raised its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after acquiring an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Enliven Therapeutics in the 4th quarter valued at about $97,000. BNP Paribas Financial Markets acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $112,000. ExodusPoint Capital Management LP purchased a new position in Enliven Therapeutics during the fourth quarter worth about $200,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Enliven Therapeutics by 17.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock worth $307,000 after buying an additional 1,980 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Up 0.3%

NASDAQ ELVN traded up $0.06 during trading on Thursday, hitting $19.66. The stock had a trading volume of 191,309 shares, compared to its average volume of 272,298. The company has a market capitalization of $964.70 million, a PE ratio of -10.35 and a beta of 0.79. The firm has a 50 day moving average price of $18.14 and a 200 day moving average price of $20.72. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $16.07, for a total transaction of $80,350.00. Following the sale, the insider now owns 997,688 shares in the company, valued at $16,032,846.16. This represents a 0.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now directly owns 990,392 shares in the company, valued at $20,629,865.36. This represents a 1.25% decrease in their position. The disclosure for this sale can be found here. Insiders sold 101,111 shares of company stock valued at $1,936,664 in the last 90 days. Company insiders own 25.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ELVN. HC Wainwright upped their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Jones Trading cut their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.